Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Seeks To Gain Technology Strength By Foreign Acquisitions (Japan)

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma Co-Chairman Hatsuo Aoki does not feel it necessary for his company or another Japanese pharmaceutical company to try to become one of the world's largest and will not attempt it. Aoki said the firm does plan to expand this year, however, by seeking mergers and acquisitions to provide it with the technological skills needed to compete on a global scale. But Aoki said in an interview that Astellas is comfortable with its current size and "we no longer have to pursue the merit of scale." He said larger Japanese firms such as Astellas would be looking to buy foreign businesses rather than local ones, to give them access to "breakthrough technologies and promising candidate drugs." (Click here for more - may require a subscription

Latest Headlines
See All
UsernamePublicRestriction

Register

SC066597

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel